Propanc Biopharma, Inc. Common Stock (PPCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($9.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Propanc Biopharma, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Propanc Biopharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Propanc Biopharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xpon Technologies Group Ltd
AU:XPN
|
-1.594x |
|
Kridhan Infra Limited
NSE:KRIDHANINF
|
-0.004x |
|
Angel Wing Metals Inc
V:AWM
|
-0.159x |
|
Bounty Oil & Gas NL
AU:BUY
|
-0.034x |
|
SKRR Exploration Inc
V:SKRR
|
-0.077x |
|
Iljeong Ind
KO:008500
|
0.046x |
|
Fon SE
WAR:FON
|
0.016x |
|
Kmc Properties ASA
OL:KMCP
|
0.039x |
Annual Cash Flow Conversion Efficiency for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Propanc Biopharma, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.91 Million | $-405.17K | -0.029x | -111.77% |
| 2024-06-30 | $-3.78 Million | $-935.12K | 0.247x | -30.21% |
| 2023-06-30 | $-3.12 Million | $-1.11 Million | 0.355x | -25.36% |
| 2022-06-30 | $-3.02 Million | $-1.44 Million | 0.475x | +27.23% |
| 2021-06-30 | $-3.07 Million | $-1.15 Million | 0.373x | -26.50% |
| 2020-06-30 | $-3.64 Million | $-1.85 Million | 0.508x | +6.05% |
| 2019-06-30 | $-4.30 Million | $-2.06 Million | 0.479x | +48.50% |
| 2018-06-30 | $-6.75 Million | $-2.18 Million | 0.323x | -18.43% |
| 2017-06-30 | $-5.44 Million | $-2.15 Million | 0.395x | -78.87% |
| 2016-06-30 | $-2.57 Million | $-4.80 Million | 1.871x | +300.52% |
| 2015-06-30 | $-3.05 Million | $-1.43 Million | 0.467x | +190.54% |
| 2014-06-30 | $-1.41 Million | $-226.44K | 0.161x | -0.95% |
| 2013-06-30 | $-792.48K | $-128.65K | 0.162x | -48.72% |
| 2012-06-30 | $-537.92K | $-170.28K | 0.317x | +338.36% |
| 2011-06-30 | $10.51 Million | $-1.40 Million | -0.133x | -112.96% |
| 2010-06-30 | $-186.90K | $-191.51K | 1.025x | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more